Heart failure & cardiomyopathies
Cost-effectiveness of digitoxin in heart failure with reduced ejection fraction in the European Union and the United States
Authors' conclusion
Digitoxin generated clinically meaningful health benefits at negligible incremental cost and remained cost-effective across every evaluated EU-27 healthcare system and the USA.
Study context
- Population
- Heart Failure with Reduced Ejection Fraction (HFrEF), all 27 EU Member States and the United States (US) (DIGIT-HF-informed model)
- Comparison
- Digitoxin add-on vs no digitoxin
- Outcome
- Cost-effectiveness (incremental costs, QALYs, ICER)
- Follow-up
- 10-year and lifetime
Methodological detailsthree-state Markov cost-utility model, multi-jurisdictional, 10 000 probabilistic simulations
- Three-state Markov cost-utility model
- Multi-jurisdictional
- 10 000 probabilistic simulations
Main finding
As reported in the abstract
Cost-effectiveness, EU-27 · 10 years
Incremental costs per patient
-€338 to +€25
Incremental quality-adjusted life-years (QALYs)
0.188-0.231
Maximum incremental cost-effectiveness ratio (ICER)
€120/QALY
Cost-saving Member States
24 of 27
Further findings
Cost-effectiveness, EU-27 · lifetime
- Incremental costs per patient
- -€79 to +€72
- Incremental QALYs
- 0.373-0.453
- Maximum ICER
- €174/QALY
- Cost-saving Member States
- 10 of 27
Probability of cost-effectiveness at €50 000/QALY, EU-27
- Probability of cost-effectiveness
- 92%
Cost-effectiveness, US · lifetime
- Lifetime savings per patient
- US$405
- QALYs gained
- 0.43
- Probability of cost-effectiveness
- 93.4%
- Cost-saving
Original publication
Cost-effectiveness of digitoxin in heart failure with reduced ejection fraction in the European Union and the United States. Eur J Heart Fail. Published 29 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →